We investigated the antitumor effects induced by the production of interleukin-12 (IL-12) or IL-18, which influence the function of T helper type 1 cells, in murine colon carcinoma cells (Colon 26). Retrovirally transduced cells with IL-12 genes that encoded both p35 and p40 (Colon 26/IL-12) lost their tumorigenicity when inoculated subcutaneously or intraperitoneally into syngeneic immunocompetent mice. Moreover, the mice that had rejected the Colon 26/IL-12 cells generated protective immunity to wild-type 
G eneration of systemic antitumor immunity is a desirable strategy for the treatment of advanced cancer. The administration of cytokines that play pivotal roles in the enhancement of the cellular immunity of the host is a possible therapeutic maneuver. However, systemic administration of recombinant cytokine(s) elicits adverse reactions that patients sometimes cannot tolerate. An alternative method is to express cytokine gene(s) in tumor cells and to generate systemic immunity in the inoculated hosts. Various cytokine genes have been tested for their activities to modulate host immunity. Among those, interleukin-2 (IL-2) has been extensively studied and was shown to be effective for many types of cancer.
1 IL-2 is secreted from T helper type 1 (Th1) cells and can activate cytotoxic killer T cells and natural killer (NK) cells. 2, 3 Th cell subsets, which differ in the pattern of cytokine production, are associated with their function in an immune response. Th1 cells secrete IL-2 and/or interferon-␥ (IFN-␥), whereas Th2 cells produce several other cytokines, such as IL-4 and IL-10. 4 Although the complex framework of immune reactions does not permit a simplified classification, it has been argued that Th1 and Th2 cells primarily operate on cell-mediated immunity, such as phagocytotic action against microbes, and on humoral immunity, respectively. 4 Modulation of the Th1/Th2 balance can affect the outcome of normal and pathological immune responses, and the antitumor response is also influenced by the equilibrium of Th1 and Th2 activities. Thus, it is reasonable to speculate that induction of a Th1-dominant state and/or differentiation from precursor cells into Th1 cells may fortify protection against tumor cells.
IL-12 is a disulfide-linked, 75-kDa heterodimeric gly-coprotein composed of a 35-kDa and a 40-kDa subunit; this glycoprotein is secreted from antigen (Ag)-stimulated macrophages and B cells in peripheral blood mononuclear cells. 5 IL-12 has pleiotropic biological functions and has a potent mitogenic activity on activated ␣␤ T, ␥␦ T, and NK cells through an IL-2-independent mechanism. 6 It also stimulates IFN-␥ secretion from peripheral blood T and NK cells 7 and can enhance the activity of cytotoxic killer T cells. In particular, IL-12 is an obligatory factor for the generation and proliferation of Th1 cells 8 and can induce an antitumor response mediated by Th1 cells. 9 The secretion of IFN-␥ from Th1 cells is also mediated by a novel cytokine, IL-18 (described previously as IFN-␥-producing factor). 10 The functions of IL-18 are to enhance NK activity and the expression of IL-2 receptor on T cells. It also plays a role in the development and activation of Th1 cells but not Th2 cells. 10 Although the receptor of IL-18 has been recently identified, 11 its biological significance is under investigation. In this study, we tested whether the cytokines, which act on Th1 cells, can be used for cancer gene therapy. We transduced murine colon carcinoma (Colon 26) cells with IL-12 or IL-18 gene and inoculated them into syngeneic immunocompetent and immunocompromised mice to investigate whether an antitumor response can be generated.
MATERIALS AND METHODS

Cells and animals
BALB/c and BALB/c nu/nu mice (6-to 8-week-old females) were purchased from Japan SLC (Hamamatsu, Japan); BALB/c scid/scid mice (6-to 8-week-old females) were obtained from Nippon Clea (Tokyo, Japan). Colon 26, a carcinogen-induced undifferentiated adenocarcinoma cell line, 12, 13 was supplied by Dr. Hamuro (Ajinomoto, Tokyo, Japan). Both ecotropic 2 and amphotropic PA317 packaging cells were obtained from the American Type Culture Collection (Manassas, Va). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf sera.
Isolation of murine IL-12 and IL-18 gene
A reverse transcription-based polymerase chain reaction was used to clone mouse IL-12 or IL-18 genes. Total RNA from unstimulated and Zysorbin-stimulated spleen cells of C57BL/6 mice was used to synthesize p35 and p40 IL-12 subunit cDNA, respectively. Poly(A ϩ ) mRNA from lipopolysaccharide (10 g/mL)-stimulated spleen cells of BALB/c mice was used to synthesize IL-18 cDNA. The primers used were as follows: for amplification of the p35 subunit, 5Ј-GGAATTCGCCGGC-TATCCAGACAATTATA-3Ј (as a 5Ј primer) and 5Ј-GG-GATCCTGTTTCCTATCTGTGTGAGGAG-3Ј (as a 3Ј primer); for amplification of the p40 subunit, 5Ј-GGAATTCGC-ACATCAGACCAGGCAGCTCG-3Ј (as a 5Ј primer) and 5Ј-GGGATCCTCCAACGTTGCATCCTAGGATC-3Ј (as a 3Ј primer); for amplification of IL-18, 5Ј-ATTACTCGAG-GAACAATGGCTGCCATGTC-3Ј (as a 5Ј primer) and 5Ј-ATTACTCGAGAAGGCGCATGTGTGCTAATC-3Ј (as a 3Ј primer). Amplification was performed according to the manufacturer's recommendations (Perkin-Elmer Cetus, Norwalk, Conn) and consisted of 30 cycles under the following conditions: 1 minute at 94°C for denaturation, 1 minute at 65°C and 60°C for primer annealing of IL-12 and IL-18, respectively, and 2 minutes at 72°C for primer extension. The sequences of the polymerase chain reaction products were confirmed and matched to the published sequences. 16 was used to harbor cloned cDNAs. Because the coexpression of both p35 and p40 subunits is necessary for the secretion of biologically active IL-12, 17 the internal ribosome entry site gene of encephalomyocarditis virus 18 from pCITE-2 (Novagen, Madison, Wis) was used. The vector DNA bearing the cDNA was transfected into ecotropic 2 cells by lipofectin reagent (Life Technologies, Gaithersburg, Md); after the drug selection with G418 (Life Technologies), cell-free supernatants of G418-resistant clones were saved as a retrovirus stock. The culture supernatants containing retrovirus were incubated with amphotropic PA317 cells in the presence of 8 g/mL polybrene (Aldrich, Milwaukee, Wis) for infection. 19 The G418-resistant PA317 cells were cloned, and the supernatants of the cloned cells were used to transduce Colon 26 cells as described above.
14,15
Construction of retrovirus
Establishment of transduced Colon 26 cells with IL-12 or IL-18 gene
Retrovirally transduced Colon 26 cells were cloned, and a clone (Colon 26/IL-12) that produced the highest amount of IL-12 was selected. The amounts of IL-12 secreted into the culture supernatants were determined with an enzyme-linked immunosorbent assay kit (Endogen, Cambridge, Mass). We also selected a clone (Colon 26/IL-18) that produced the highest amount of IL-18 transcript. In this study, Northern blot analysis was used, because an immunosorbent assay system to detect IL-18 was not available. The production of IFN-␥ from spleen cells was tested as follows: Spleen cells (1 ϫ 10 6 /well) from BALB/c mice were cultured in a 24-multiwell plates (1 mL/well) coated with anti-CD3 antibody (Ab) (0.5 g/mL) for 40 hours with 0.25 mL of the supernatants of Colon 26/IL-18 cells (from 5 ϫ 10 5 cells/mL/48 hours). 15 The amount of IFN-␥ in the supernatants of cultured spleen cells was measured with an enzyme-linked immunosorbent assay kit (Endogen). 
Flow cytometry
Northern blot analysis
RNA (15 g) was subjected to agarose gel electrophoresis and was transferred to a nylon filter. The IL-18 cDNA was labeled with [ 32 P]deoxycytidine triphosphate and used as a probe. Hybridization was performed in a solution of 50% formamide, 5ϫ standard saline citrate, 50 mM NaH 2 PO 4 , 2ϫ Denhardt's solution, 0.1% sodium dodecyl sulfate, and 0.1 mg/mL salmon sperm DNA at 42°C for 12 hours. The filter was washed with the solution of 0.2ϫ standard saline phosphate/ethylenediami-netetraacetic acid and 0.1% sodium dodecyl sulfate several times at 50°C. Immunohistochemistry Sections (4-or 5-m thickness) from frozen tumors were reacted with anti-mouse CD11b, anti-mouse CD31, anti-mouse CD54, anti-mouse CD90, or anti-mouse CD106 Ab followed by biotinylated anti-rat IgG or anti-hamster IgG Ab (Vector Laboratories, Burlingame, Calif). The staining using horseradish peroxidase was performed according to the manufacturer's instructions (Vector Laboratories). Table 1) . The average survival of the mice that were injected i.p. with wt cells was 16.3 days, but all of the mice inoculated with Colon 26/IL-12 survived until the end of the observation period (Table 1) . Thus, the expression of IL-12 genes in Colon 26 cells can induce an antitumor effect in the inoculated hosts. However, in the experimental lung metastasis model using an i.v. injection through the tail vein, the survival days of the mice in these two groups were not different (P ϭ .393, Table 1 ).
Animal studies
RESULTS
In vitro analysis of transduced cells
To examine whether protective immunity was generated in the mice that had rejected Colon 26/IL-12 cells, we reinoculated a lethal dose of wt cells into the mice. Irrespective of the route of injection, all of the mice rejected the wt cells when subsequently challenged (Table 1). Systemic immunity was generated in the mice that received Colon 26/IL-12 cells, and they became resistant even to wt cells injected i.v.
Antitumor effect of the inoculation of Colon 26/IL-18 cells
We also examined whether the antitumor effect could be achieved by inoculating Colon 26/IL-18 cells into immunocompetent mice. The mice that were inoculated s.c. with Colon 26/IL-18 cells developed small tumors that regressed thereafter. Consequently, they survived until the end of the observation period (Table 2) . However, the survival days of the mice that had been inoculated i.p. or i.v. with Colon 26/IL-18 cells were not statistically different from those of the mice that received wt cells (Table 2 ). Thus, the antitumor effect produced by Colon 26/IL-18 cells was influenced by the inoculation routes. The generation of systemic immunity was also observed in the mice that had rejected s.c. tumors of Colon 26/IL-18 cells. The mice survived even though they were inoculated s.c. or i.v. with a lethal dose of wt cells (Table 2) .
Immunohistochemical analysis
We immunohistochemically examined the tumors of wt, Colon 26/IL-12, or Colon 26/IL-18 cells. We observed that CD11b ϩ and CD90 ϩ cells migrated into the respective tumors that had developed in immunocompetent mice, but the degree of cell infiltration among the tumors was not different (data not shown). However, the number of CD31 ϩ endothelial cells in similar-sized tumors remarkably decreased in the tumors of Colon 26/IL-12 or Colon 26/IL-18 cells compared with wt tumors (Fig 2) . The expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) (CD54) and vascular cell adhesion molecule-1 (VCAM-1) (CD106) increased on the vascular endothelium in the stroma of Colon 26/IL-12 tumors (Fig 3, A , B, D, and E). However, the up-regulated expression was not observed in the blood vessels within the Colon 26/IL-12 tumors (data not shown). In contrast, the expression of these molecules on the endothelium both in the stroma of Colon 26/IL-18 and within the tumors remained the same as that in wt tumors (Fig 3, A, C, D , and F).
Antitumor effect in immunocompromised hosts
We tested the antitumor effect of the cytokine producers in syngeneic nude or severe combined immunodeficient (SCID) mice. The survival days of the nude mice that had been inoculated with wt cells were not statistically different from those of the immunocompetent mice with wt cells (Tables 1 and 3, 2 ϭ 1.17, df ϭ1, P ϭ .279). The nude mice that received Colon 26/IL-12 cells developed tumors, but survival was significantly prolonged compared with the nude mice injected with wt cells (Table 3, 2 ϭ 12.0, df ϭ 1, P ϭ .0005). The antitumor effect of Colon 26/IL-12 cells was also achieved in nude mice, although the effect was not sufficient to eliminate s.c. tumors as observed in immunocompetent mice. In contrast, the survival days of the nude mice inoculated with Colon 26/IL-18 cells was not different from that of the nude mice inoculated with wt cells (Table 3, 2 ϭ 0.114, dfϭ1, P ϭ .736).
Survival of the SCID mice inoculated with wt cells was not statistically different from that of the nude mice with wt cells (Table 3 , P ϭ .0856), but was significantly shorter than the immunocompetent mice with wt cells (Tables 2 and 3, 2 ϭ 11.7, df ϭ 1, P ϭ .0006). Consequently, the survival of the SCID mice inoculated with Colon 26/IL-18 cells became longer than that of the SCID mice with wt cells ( 2 ϭ 11.7, df ϭ 1, P ϭ .0006) but was not statistically different from that of the nude mice injected with Colon 26/IL-18 cells ( 2 ϭ 0.647, df ϭ 1, P ϭ .421) or that of nude mice with wt cells ( 2 ϭ 0.689, df ϭ 1, P ϭ .406). Thus, the antitumor effect caused by inoculated Colon 26/IL-18 cells was not 
DISCUSSION
In this study, we have shown that an inoculation of Colon 26 cells transduced with IL-12 or IL-18 gene produced an antitumor effect in syngeneic immunocompetent mice. Protective immunity was also acquired in (Tables 1 and 2 ). This systemic immunity is tumor-specific, because the mice that acquired a resistance to wt cells developed tumors of syngeneic fibrosarcoma or lymphoma cells when subsequently challenged (data not shown). The antitumor activity was influenced by the route of administration. Inoculation s.c. could effectively elicit an antitumor response. Although the reason for these differential antitumor activities remains uncharacterized, professional Ag-presenting cells such as dendritic cells may access tumor cells more efficiently in s.c. tissues. Previous studies also demonstrated that the antitumor immunity elicited via an i.v. injection was not easily acquired compared with that by s.c. inoculation. 21, 22 The differential tumorigenicity of Colon 26/IL-12 cells between immunocompetent and nude mice revealed the requirement of ␣␤ T cells for the rejection of Colon 26/IL-12 cells (Tables 1 and 3 ). Because the survival of the nude mice inoculated with Colon 26/IL-12 cells was longer than that of the SCID mice inoculated with Colon 26/IL-12 cells, ␥␦ T, B, and/or NK1 T cells 23 may be involved in the antitumor response. Moreover, the SCID mice injected with Colon 26/IL-12 cells survived longer than those with wt cells. Granulocyte, macrophage, and/or NK cells are thereby also possibly required for an IL-12-mediated immune response. It has been demonstrated that IL-12 is effective in NK-deficient beige mice or anti-asialo GM1 Ab-treated mice, 24 and NK1 T cells were recently reported to be essential for IL-12-mediated antitumor activity. 25 Based on our results and others, we speculate that ␣␤ T cells are indispensable, but that other cell types are also responsible for IL-12-mediated antitumor immunity. Because NK1 T cells cannot be generated in SCID mice 26 and NK cells are not deeply involved in the IL-12-mediated reaction, CD11b ϩ macrophages, for example, are one of the candidate cells that possibly contribute to the response.
On the other hand, IL-12 inhibits neovascularization and this suppressed angiogenesis is mediated by IFN-␥. 27 We showed a decreased number of CD31 ϩ cells in Colon 26/IL-12-and Colon 26/IL-18-derived tumors (Fig 2) . Although IL-18 is not reported to inhibit angiogenesis, the decreased vascular formation observed in this study can reflect the shared property between the two cytokines to enhance IFN-␥ production. The inhibition of angiogenesis is not influenced by the immunocompetency of hosts, 27, 28 and the impaired angiogenesis may be one of the mechanisms that produces an antitumor response. Moreover, we showed up-regulated expression of adhesion molecules (ICAM-1 and VCAM-1) on the vascular endothelium in peritumoral regions (stroma) but not in Colon 26/IL-12 tumor masses (Fig  3) . The enhanced expression on the endothelium favors the recruitment of lymphocytes and consequently could promote the accessibility of these cells to tumor cells. 29 Ogawa et al 30 showed that the administration of recombinant IL-12 indeed up-regulated the expression of vascular ICAM-1 and VCAM-1 molecules. However, the effect of IL-18 on the expression of these molecules has not been well studied, and the present study showed that IL-18 could not elevate the expression of the adhesion molecules (Fig 3) . Thus, the differential antitumor activity between the two cytokines may be attributable in part to the difference in the modulated expression of these molecules.
We showed the requirement of ␣␤ T cells for an IL-18-mediated response when injected s.c. (Tables 2  and 3 ). Because the survival of immunocompromised mice inoculated with Colon 26/IL-18 or wt cells was not different (Table 3) , NK cells may not be actively involved in the antitumor response. However, previous studies have shown that depletion of NK cells from immunocompetent mice using anti-asialo GM1 Ab abrogated the IL-18-mediated antitumor effect. 31 (Table 2) , secretion of IL-18 might be inefficient to fully activate the immunocompetent cells. We also found that the loss of tumorigenicity of Colon 26/IL-18 cells when they were inoculated s.c. in immunocompetent mice was abolished when mice were pretreated with anti-IL-12 Ab (data not shown). Because the expression of IL-18 receptors on lymphocytes was efficiently enhanced by IL-12, 35 priming with IL-12 is required to sufficiently activate T and NK cells by IL-18-producing tumors.
Because previous reports have suggested that combinatory applications of cytokines are effective, 36, 37 we examined the synergistic effect, if any, of IL-2-and IL-12-producing cells using the experimental i.p. dissemination model (Table 4 ). Inoculation i.p. of Colon 26/ IL-2 cells into immunocompetent mice that previously received wt cells prolonged survival. In contrast, inoculation of Colon 26/IL-12 cells did not have a beneficial effect, although Colon 26/IL-12 cells injected i.p. were rejected and subsequently generated protective immunity in the inoculated mice (Table 1 ). In the present study, any synergistic effect of Colon 26/IL-2 and Colon 26/IL-12 cells was not achieved, and the antitumor effect of the mixed population seemed to be solely due to the inoculated Colon 26/IL-2 cells. In contrast, a synergistic effect produced by the expression of IL-12 and CD80 costimulatory molecule in tumor cells was reported. 38, 39 Because IL-12 functions in an afferent phase of Th1 induction and IL-2 operates in an efferent phase of Th1 action, successive application of the cytokines may be important to obtain an optimal antitumor effect.
In this study, we showed that the production of cytokines that induce Th1 cells in tumor cells can generate an antitumor response. We tested other cytokines that are secreted from Th2 cells (IL-4, IL-6, and IL-10) and found that the expression of these cytokines in Colon 26 cells did not achieve an antitumor effect (data not shown). Other studies also suggested that better therapeutic effects in am antitumor response were associated with systemic activation of Th1 rather than Th2 cells, 40 and that a cytokine profile at the site of the antitumor inflammatory response was Th1-dominant. 41 Both cytokines examined in this study can induce the generation of Th1 cells and IFN-␥ production; however, the mechanism of the antitumor response is independent each other. 32 Because the distribution of the receptors is not identical, 42 synergistic action using both cytokines can be expected. 32, 43 However, the complexity of the immune response suggests that modulation of cytokine expression may not be adequate to induce enough antitumor activity. Enhancement of Ag processing in professional Ag-presenting cells by up-regulating costimulatory molecules 39 and/or CD40 ligand 44 should be considered to attain optimal antitumor immunity.
